{"id":88689,"date":"2023-10-05T14:38:29","date_gmt":"2023-10-05T12:38:29","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/"},"modified":"2025-10-13T15:24:50","modified_gmt":"2025-10-13T13:24:50","slug":"gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/","title":{"rendered":"Gisela Lorente, nueva CEO de la biotecnol\u00f3gica Aptadel Therapeutics"},"content":{"rendered":"<p><strong><a href=\"https:\/\/www.pcb.ub.edu\/es\/empresa\/aptadel-therapeutics\/\" target=\"_blank\" rel=\"noopener\">Aptadel Therapeutics<\/a> -una spinoff en etapa precl\u00ednica del Instituto de Investigaci\u00f3n Biom\u00e9dica de\u00a0Bellvitge\u00a0(<a href=\"https:\/\/idibell.cat\/en\/\" target=\"_blank\" rel=\"noopener\">IDIBELL<\/a>), con sede en el Parque Cient\u00edfico de Barcelona y centrada en el desarrollo de una nueva plataforma de terapias de ARN para el c\u00e1ncer infantil \u2013 ha nombrado a Gisela Lorente, hasta ahora directora cient\u00edfica, nueva CEO de la compa\u00f1\u00eda.<\/strong><\/p>\n<p>Gisela Lorente es doctora en Biolog\u00eda Molecular por la Universidad de Barcelona, y cuenta con m\u00e1s de 8 a\u00f1os de experiencia como investigadora cient\u00edfica en oncolog\u00eda. Empez\u00f3 su trayectoria en el mundo de la innovaci\u00f3n y tech-transfer en el Reino Unido, y posteriormente, en 2016, se incorpor\u00f3 al IDIBELL, donde fue responsable del Departamento de Innovaci\u00f3n y Transferencia Tecnol\u00f3gica durante cinco a\u00f1os. All\u00ed acompa\u00f1\u00f3 el proyecto de Aptadel Therapeutics, convirti\u00e9ndose en una persona clave en la creaci\u00f3n de la spinoff, incorpor\u00e1ndose a la compa\u00f1\u00eda finalmente como cofundadora y CSO.<\/p>\n<p>Lorente acumula una amplia experiencia en el campo de la transferencia de tecnolog\u00eda y conocimiento, la evaluaci\u00f3n y valorizaci\u00f3n de los resultados de la investigaci\u00f3n y su protecci\u00f3n mediante propiedad industrial\/intelectual, as\u00ed como en la b\u00fasqueda de financiaci\u00f3n y traslaci\u00f3n al mercado. Ha sido la responsable de la gesti\u00f3n de m\u00e1s de 150 proyectos innovadores, y ha participado en la constituci\u00f3n de cuatro startups.<\/p>\n<p>Ahora, en esta nueva etapa como\u00a0CEO\u00a0de\u00a0Aptadel, la cient\u00edfica y emprendedora asume la responsabilidad de liderar el plan estrat\u00e9gico de la\u00a0spinoff, enfocado en su crecimiento y rentabilidad, as\u00ed como el reto de convertirla en un referente en el tratamiento del c\u00e1ncer infantil con terapias de RNA.<\/p>\n<p>\u201cMis principales objetivos al frente de la compa\u00f1\u00eda es conseguir financiaci\u00f3n para validar los estudios IND (<em>Investigational\u00a0New\u00a0Drug<\/em>) y llevar la mol\u00e9cula candidata a ensayos cl\u00ednicos en pacientes con Sarcoma de Ewing, e iniciar nuevos programas de desarrollo en otras variedades de tumores pedi\u00e1tricos y adultos\u201d, explica <strong>Lorente<\/strong>.<\/p>\n<p>Aptadel Therapeutics, fundada a finales de 2020, es una spinoff precl\u00ednica del Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL), impulsada por el <strong>Dr. Oscar Mart\u00ednez-Tirado<\/strong>, que ha proporcionado la principal tecnolog\u00eda relacionada con el proyecto, y la <strong>Dra. Gisela Lorente<\/strong>. En la constituci\u00f3n de la compa\u00f1\u00eda tambi\u00e9n particip\u00f3 la Fundaci\u00f3n Alba P\u00e9rez, que re\u00fane un s\u00f3lido sindicato de inversores privados.<\/p>\n<p>Su misi\u00f3n es desarrollar una nueva plataforma de terapias de RNA para tratar m\u00faltiples tipos de c\u00e1ncer, especialmente c\u00e1nceres infantiles como el Sarcoma de Ewing, haciendo uso de una tecnolog\u00eda revolucionaria. Esta plataforma consiste en el uso de apt\u00e1meros de RNA conjugados con agentes terap\u00e9uticos, como mol\u00e9culas de ARN o f\u00e1rmacos quimioter\u00e1picos, dirigidos a diferentes tumores diana, que son liberados solo all\u00e1 donde hace falta, mejorando la efectividad de los tratamientos y evitando los efectos secundarios.<\/p>\n<p>Aptadel Therapeutics -que forma parte de la primera generaci\u00f3n de empresas que participan en la aceleradora BCN Health Booster- cerr\u00f3 en diciembre de 2020 su primera ronda de financiaci\u00f3n, en la que levant\u00f3 1,75 M\u20ac. El 2022 recibi\u00f3 una beca Eurostars (Eureka &#8211; Comisi\u00f3n Europea) por importe de 1,87 M\u20ac para desarrollar la primera terapia dirigida contra el c\u00e1ncer infantil Sarcoma de Ewing, basada en apt\u00e1meros de ARN conjugados a siRNA, y tambi\u00e9n fue beneficiaria de una ayuda de 1,78 M\u20ac del Programa Estatal de I+D+I Orientado a los Retos de la Sociedad (Agencia Estatal de Investigaci\u00f3n) y una subvenci\u00f3n de 325.000 del Programa Neotec del Centro para el Desarrollo Tecnol\u00f3gico y la Innovaci\u00f3n (CDTI).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aptadel Therapeutics -una spinoff en etapa precl\u00ednica del Instituto de Investigaci\u00f3n Biom\u00e9dica de\u00a0Bellvitge\u00a0(IDIBELL), con sede en el Parque Cient\u00edfico de Barcelona y centrada en el desarrollo de una nueva plataforma&#8230;<\/p>\n","protected":false},"author":14,"featured_media":88662,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[356],"tags":[],"class_list":["post-88689","post","type-post","status-publish","format-standard","has-post-thumbnail","category-empresas"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gisela Lorente, nueva CEO de la biotecnol\u00f3gica Aptadel Therapeutics - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gisela Lorente, nueva CEO de la biotecnol\u00f3gica Aptadel Therapeutics - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Aptadel Therapeutics -una spinoff en etapa precl\u00ednica del Instituto de Investigaci\u00f3n Biom\u00e9dica de\u00a0Bellvitge\u00a0(IDIBELL), con sede en el Parque Cient\u00edfico de Barcelona y centrada en el desarrollo de una nueva plataforma...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-05T12:38:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T13:24:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/10\/aptadel_10-23-1_web.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"Gisela Lorente, nueva CEO de la biotecnol\u00f3gica Aptadel Therapeutics\",\"datePublished\":\"2023-10-05T12:38:29+00:00\",\"dateModified\":\"2025-10-13T13:24:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\\\/\"},\"wordCount\":630,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/aptadel_10-23-1_web.jpg\",\"articleSection\":[\"EMPRESAS\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\\\/\",\"name\":\"Gisela Lorente, nueva CEO de la biotecnol\u00f3gica Aptadel Therapeutics - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/aptadel_10-23-1_web.jpg\",\"datePublished\":\"2023-10-05T12:38:29+00:00\",\"dateModified\":\"2025-10-13T13:24:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/aptadel_10-23-1_web.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/aptadel_10-23-1_web.jpg\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gisela Lorente, nueva CEO de la biotecnol\u00f3gica Aptadel Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gisela Lorente, nueva CEO de la biotecnol\u00f3gica Aptadel Therapeutics - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/","og_locale":"es_ES","og_type":"article","og_title":"Gisela Lorente, nueva CEO de la biotecnol\u00f3gica Aptadel Therapeutics - Parc Cient\u00edfic de Barcelona","og_description":"Aptadel Therapeutics -una spinoff en etapa precl\u00ednica del Instituto de Investigaci\u00f3n Biom\u00e9dica de\u00a0Bellvitge\u00a0(IDIBELL), con sede en el Parque Cient\u00edfico de Barcelona y centrada en el desarrollo de una nueva plataforma...","og_url":"https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2023-10-05T12:38:29+00:00","article_modified_time":"2025-10-13T13:24:50+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/10\/aptadel_10-23-1_web.jpg","type":"image\/jpeg"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Paula Ca\u00f1al","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"Gisela Lorente, nueva CEO de la biotecnol\u00f3gica Aptadel Therapeutics","datePublished":"2023-10-05T12:38:29+00:00","dateModified":"2025-10-13T13:24:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/"},"wordCount":630,"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/10\/aptadel_10-23-1_web.jpg","articleSection":["EMPRESAS"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/","url":"https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/","name":"Gisela Lorente, nueva CEO de la biotecnol\u00f3gica Aptadel Therapeutics - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/10\/aptadel_10-23-1_web.jpg","datePublished":"2023-10-05T12:38:29+00:00","dateModified":"2025-10-13T13:24:50+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/10\/aptadel_10-23-1_web.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/10\/aptadel_10-23-1_web.jpg","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/gisela-lorente-nueva-ceo-de-la-biotecnologica-aptadel-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"Gisela Lorente, nueva CEO de la biotecnol\u00f3gica Aptadel Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/88689","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=88689"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/88689\/revisions"}],"predecessor-version":[{"id":88690,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/88689\/revisions\/88690"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/88662"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=88689"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=88689"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=88689"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}